6657 — Energenesis Biomedical Co Income Statement
0.000.00%
Last trade - 00:00
- TWD4.20bn
- TWD3.51bn
- TWD7.16m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.25 | 7.08 | 7.49 | 7.35 | 7.16 |
Cost of Revenue | |||||
Gross Profit | 3.87 | 4.83 | 5.36 | 5.17 | 5.23 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 159 | 141 | 130 | 279 | 269 |
Operating Profit | -153 | -134 | -122 | -272 | -262 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -150 | -129 | -120 | -266 | -260 |
Provision for Income Taxes | |||||
Net Income After Taxes | -150 | -129 | -120 | -266 | -260 |
Net Income Before Extraordinary Items | |||||
Net Income | -150 | -129 | -120 | -266 | -260 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -150 | -129 | -120 | -266 | -260 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.83 | -2.19 | -2 | -3.99 | -3.61 |
Dividends per Share |